FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Published: | Updated:
Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Approval Alert | Treosulfan/Fludarabine Injection for HSCT Conditioning in AML/MDS
Advertisement
Advertisement
Trending on CancerNetwork
1
124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer
2
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
3
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
4
123 Real-World Patient and Caregiver Experiences With Breast Cancer (BC) Risk of Recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis
5